Health officials have given a life-extending drug the green light for widespread NHS, giving hope to thousands of men facing a "death sentence" from prostate cancer.
The National Institute for Health and Care Excellence (Nice) said the drug enzalutamide, also known as xtandi, should be considered for use in the treatment of men with hormone relapsed prostate cancer that has spread to other parts of the body.
Nice said in its draft guidance that it was pleased to recommend the drug, which is manufactured by Astellas Pharma, for patients who have few other treatment options left.
More top news
Foreign criminals are costing the UK £850m, with the number jailed or deported remaining broadly unchanged since 2006, according to a report
Toys R Us has scrapped its four collectible dolls based on the characters of the hit TV series Breaking Bad after a campaign by a US mother
Late actress Lynda Bellingham shared how she planned to spend Christmas during a moving final interview on Loose Women to be broadcast later